Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus - PubMed (original) (raw)
Clinical Trial
. 2009 Jun;60(6):1785-96.
doi: 10.1002/art.24557.
Affiliations
- PMID: 19479852
- DOI: 10.1002/art.24557
Free article
Clinical Trial
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus
Yihong Yao et al. Arthritis Rheum. 2009 Jun.
Free article
Abstract
Objective: Type I interferons (IFNs) play an important role in the pathogenesis of systemic lupus erythematosus (SLE). This phase Ia trial was undertaken to evaluate the safety, pharmacokinetics, and immunogenicity of anti-IFNalpha monoclonal antibody (mAb) therapy in SLE. During the trial, we also examined whether overexpression of an IFNalpha/beta-inducible gene signature in whole blood could serve as a pharmacodynamic biomarker to evaluate IFNalpha neutralization and investigated downstream effects of neutralizing IFNalpha on BAFF and other key signaling pathways, i.e., granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-10 (IL-10), tumor necrosis factor alpha (TNFalpha), and IL-1beta, in SLE.
Methods: Affymetrix Human Genome U133 Plus 2.0 microarrays were used to profile whole blood and lesional skin of patients receiving standard therapy for mild to moderate SLE. Selected IFNalpha/beta-inducible proteins were analyzed by immunohistochemistry.
Results: With the study treatment, we observed anti-IFNalpha mAb-specific and dose-dependent inhibition of overexpression of IFNalpha/beta-inducible genes in whole blood and skin lesions from SLE patients, at both the transcript and the protein levels. In SLE patients with overexpression of messenger RNA for BAFF, TNFalpha, IL-10, IL-1beta, GM-CSF, and their respective inducible gene signatures in whole blood and/or skin lesions, we observed a general trend toward suppression of the expression of these genes and/or gene signatures upon treatment with anti-IFNalpha mAb.
Conclusion: IFNalpha/beta-inducible gene signatures in whole blood are effective pharmacodynamic biomarkers to evaluate anti-IFNalpha mAb therapy in SLE. Anti-IFNalpha mAb can neutralize overexpression of IFNalpha/beta-inducible genes in whole blood and lesional skin from SLE patients and has profound effects on signaling pathways that may be downstream of IFNalpha in SLE.
Trial registration: ClinicalTrials.gov NCT00299819.
Similar articles
- Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B; Lupus Interferon Skin Activity (LISA) Study Investigators. Merrill JT, et al. Ann Rheum Dis. 2011 Nov;70(11):1905-13. doi: 10.1136/ard.2010.144485. Epub 2011 Jul 27. Ann Rheum Dis. 2011. PMID: 21798883 Clinical Trial. - Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
Yao Y, Higgs BW, Richman L, White B, Jallal B. Yao Y, et al. Arthritis Res Ther. 2010;12 Suppl 1(Suppl 1):S6. doi: 10.1186/ar2887. Epub 2010 Apr 14. Arthritis Res Ther. 2010. PMID: 20392292 Free PMC article. Review. - Anti-interferon alpha treatment in SLE.
Kirou KA, Gkrouzman E. Kirou KA, et al. Clin Immunol. 2013 Sep;148(3):303-12. doi: 10.1016/j.clim.2013.02.013. Epub 2013 Mar 1. Clin Immunol. 2013. PMID: 23566912 Review. - Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells.
Eloranta ML, Lövgren T, Finke D, Mathsson L, Rönnelid J, Kastner B, Alm GV, Rönnblom L. Eloranta ML, et al. Arthritis Rheum. 2009 Aug;60(8):2418-27. doi: 10.1002/art.24686. Arthritis Rheum. 2009. PMID: 19644885 - Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Kirou KA, et al. Arthritis Rheum. 2005 May;52(5):1491-503. doi: 10.1002/art.21031. Arthritis Rheum. 2005. PMID: 15880830
Cited by
- Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus.
Yuan Y, Kasar S, Underbayev C, Vollenweider D, Salerno E, Kotenko SV, Raveche E. Yuan Y, et al. Mol Immunol. 2012 Sep;52(2):61-70. doi: 10.1016/j.molimm.2012.04.007. Epub 2012 May 11. Mol Immunol. 2012. PMID: 22578383 Free PMC article. - Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets.
Cecchi I, Radin M, Rodríguez-Carrio J, Tambralli A, Knight JS, Sciascia S. Cecchi I, et al. Expert Rev Clin Immunol. 2021 Apr;17(4):395-406. doi: 10.1080/1744666X.2021.1901581. Epub 2021 Mar 30. Expert Rev Clin Immunol. 2021. PMID: 33686921 Free PMC article. Review. - Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside.
Squatrito D, Emmi G, Silvestri E, Ciucciarelli L, D'Elios MM, Prisco D, Emmi L. Squatrito D, et al. Auto Immun Highlights. 2014 Aug 14;5(2):33-45. doi: 10.1007/s13317-014-0058-y. eCollection 2014 Sep. Auto Immun Highlights. 2014. PMID: 26000154 Free PMC article. Review. - Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort.
Willis R, Seif AM, McGwin G Jr, Martinez-Martinez LA, González EB, Dang N, Papalardo E, Liu J, Vilá LM, Reveille JD, Alarcón GS, Pierangeli SS. Willis R, et al. Lupus. 2012 Jul;21(8):830-5. doi: 10.1177/0961203312437270. Epub 2012 Feb 17. Lupus. 2012. PMID: 22343096 Free PMC article. - Genetic regulation of serum cytokines in systemic lupus erythematosus.
Kariuki SN, Niewold TB. Kariuki SN, et al. Transl Res. 2010 Mar;155(3):109-17. doi: 10.1016/j.trsl.2009.08.012. Epub 2009 Sep 25. Transl Res. 2010. PMID: 20171594 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical